The 2026 Dana-Farber Breast Cancer Course brought together leading experts to discuss new horizons and current controversies in patient care. The event featured vital updates on everything from surgical management and radiation optimization to the expanding role of ADCs and molecular diagnostics.
Dana-Farber’s Breast Oncology Center shared the top highlights on X.
“Happening now! Dana Farber Breast Cancer Course: New Horizons, Current Controversies. Hal Burstein and Ana Garrido-Castro welcoming in-person and virtual attendees.
Rinaa Punglia gives an excellent talk on radiation treatment in Breast Cancer, discussing key questions such as:
- How much?
- In whom can we give less?
- Or non at all?
Dr. Elizabeth Mittendorf delivers insights on Breast Surgery focusing on key questions in the surgical management of the axilla.
Excellent presentation by Ilana Schlam on Molecular Diagnostics and ctDNA use in Breast Cancer at today’s Dana Farber Breast Cancer Course.
Great panel discussion and audience questions at today’s Dana Farber Breast Cancer Course. Drs Harold J. Burstein, Rinaa Punglia, Elizabeth Mittendorf, Ilana Schlam discussed Breast Cancer surgery, radiation oncology, and molecular diagnostics.
Filipa Lynce delivered exciting insights on early stage TNBC in today’s Dana Farber Breast Cancer Course.
Adrienne Waks shares insights on early stage HER2+ Breast Cancer in today’s Dana Farber Breast Cancer Course.
Continuing today’s Dana Farber Breast Cancer Course with a comprehensive review of novel treatment options for early ER+ Breast Cancer presented by Erica Mayer.
Great QandA session, moderated by Dr. Ana Garrido-Castro, with Erica Mayer, Ada Waks and Filipa Lynce at the Dana Farber Breast Cancer Course.
Insightful Breast Cancer Tumor Board discussion featuring a panel of expert multidisciplinary physicians, including Dr. Beth Mittendorf, Mike Cassidy, Rinaa Punglia, Claire Smith, Leticia Varella.
Giuseppe Curigliano, our keynote speaker delivering the Schlager Lecture on Sequencing Novel Therapies in the Modern Era – Implications for Clinical Trial Design.
Excitement is rising for both the second half of the Dana Farber Breast Cancer Course, as well as the final World Cup games!
Ana Garrido-Castro gives an excellent presentation on metastatic triple negative breast cancer focusing on ADCs and immunotherapy.
Stefania Morganti shares treatment updates on the management of HER2+ Metastatic Breast Cancer, including Dana Farber recommendations for first-line and maintenance therapy.
Great overview by Stefania Morganti of the various treatment updates in the management of HER2+ Metastatic Breast Cancer in today’s Dana Farber Breast Cancer Course.
Nancy Lin presents on ER+ Metastatic Breast Cancer: SERDs, CDK4/6, PI3K, and novel endocrine agents at the Dana Farber Breast Cancer Course.
Paolo Tarantino closed out the Dana Farber Breast Cancer Course with a lively discussion on ER+ Metastatic Breast Cancer on ADCs and Beyond.”
You can also read:
ASCO Updates Breast Cancer Follow-Up Guidelines With Risk-Based Surveillance Approach
